GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Recruiting
Phase 2
Interventional Study
HIV
Alcohol
Smoking Cigarette
Cardiovascular Disease Prevention
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 89
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- Vanderbilt University Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are:
1. Does semaglutide lower the average number of alcoholic beverages participants drink per week?
2. Does semaglutide lower the average number of cigarettes participants smoke per day?
3. Does semaglutide decrease the risk for ca…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Ages 18-89
* Prior diagnosis of HIV-1
* Affiliated with Vanderbilt Comprehensive Care Clinic
* On current ART regimen for at least 90 days prior to study entry with no missed doses for at least 7 consecutive days.
* Most recent absolute CD4 count ≥ 300 cells/mm3 and drawn with…
Contacts